The role and molecular mechanism of metabolic reprogramming of colorectal cancer by UBR5 through PYK2 regulation of OXPHOS expression study
Journal of Biochemical and Molecular Toxicology · 2023
DOI: 10.1002/jbt.23376 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Biochemical and Molecular Toxicology, 2023. Verfasst von Rong Qin und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Yan'an Hospital Affiliated to Kunming Medical University, Kunming City, Yunnan, China. Hauptthemen laut MEDLINE: Focal Adhesion Kinase 2, Colorectal Neoplasms. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Yunnan Province Department of Science and Technology-Kunming Medical University Joint Special Project.
Abstract (Originalsprache)
Colorectal carcinoma (CRC) is the third most malignant tumor in the world, but the key mechanisms of CRC progression have not been confirmed. UBR5 and PYK2 expression levels were detected by RT‐qPCR. The levels of UBR5, PYK2, and mitochondrial oxidative phosphorylation (OXPHOS) complexes were detected by western blot analysis. Flow cytometry was used to detect ROS activity. The CCK‐8 assay was used to assess cell proliferation and viability. The interaction between UBR5 and PYK2 was detected by immunoprecipitation. A clone formation assay was used to determine the cell clone formation rate. The ATP level and lactate production of each group of cells were detected by the kit. EdU staining was performed for cell proliferation.Transwell assay was performed for cell migration ability. For the CRC nude mouse model, we also observed and recorded the volume and mass of tumor‐forming tumors. The expression of UBR5 and PYK2 was elevated in both CRC and human colonic mucosal epithelial cell lines, and knockdown of UBR5 had inhibitory effects on cancer cell proliferation and cloning and other behaviors in the CRC process by knockdown of UBR5 to downregulate the expression of PYK2, thus inhibiting the OXPHOS process in CRC; rotenone (OXPHOS inhibitor) treatment enhanced all these inhibitory effects. Knockdown of UBR5 can reduce the expression level of PYK2, thus downregulating the OXPHOS process in CRC cell lines and inhibiting the CRC metabolic reprogramming process.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology, Yan'an Hospital Affiliated to Kunming Medical University, Kunming City, Yunnan, China.
- Key Laboratory of Tumor Immunological Prevention and Treatment of Yunnan Province, Kunming City, Yunnan, China.
ORCID-Profile: Hui Wang
Förderung
- Yunnan Province Department of Science and Technology-Kunming Medical University Joint Special Project
Zitieren
APA
Qin, R., Huang, Y., Yao, Y., Wang, L., Zhang, Z., Huang, W., Su, Y., Zhang, Y., Guan, A., & Wang, H. (2023). The role and molecular mechanism of metabolic reprogramming of colorectal cancer by UBR5 through PYK2 regulation of OXPHOS expression study. Journal of Biochemical and Molecular Toxicology. https://doi.org/10.1002/jbt.23376
Vancouver
Qin R, Huang Y, Yao Y, Wang L, Zhang Z, Huang W, et al. The role and molecular mechanism of metabolic reprogramming of colorectal cancer by UBR5 through PYK2 regulation of OXPHOS expression study. Journal of Biochemical and Molecular Toxicology. 2023. doi:10.1002/jbt.23376
BibTeX
@article{Qin2023,
author = {Qin, Rong and Huang, Yun and Yao, Ying and Wang, Likun and Zhang, Zhibo and Huang, Weikang and Su, Yu and Zhang, Yulu and Guan, Aoran and Wang, Hui},
title = {The role and molecular mechanism of metabolic reprogramming of colorectal cancer by UBR5 through PYK2 regulation of OXPHOS expression study},
journal = {Journal of Biochemical and Molecular Toxicology},
year = {2023},
doi = {10.1002/jbt.23376}
}
EUVIMED